Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ironwood Pharmaceuti (NQ: IRWD ) 6.790 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ironwood Pharmaceuti < Previous 1 2 3 4 5 6 Next > Why VectivBio Shares Are Surging Monday May 22, 2023 VectivBio Holding AG (NASDAQ: VECT) shares are trading higher Monday after GI-focused healthcare company Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) agreed to Via Benzinga VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion May 22, 2023 Both companies are working on treatments for gastrointestinal diseases. Via Investor's Business Daily Benzinga Pro's Top 5 Stocks To Watch For Monday, May 22, 2023: MU, RKT, DLTR, LDOS, IRWD May 22, 2023 Micron Technology (MU) - Shares were down about 4% Monday morning following a report the Chinese government found cybersecurity issues related to Micron's products. Chinese officials have asked Via Benzinga Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases May 22, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Recap: Ironwood Pharmaceuticals Q1 Earnings May 04, 2023 Via Benzinga Earnings Scheduled For February 16, 2023 February 16, 2023 Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... Via Benzinga Earnings Outlook For Ironwood Pharmaceuticals February 15, 2023 Via Benzinga Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference May 09, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023 May 08, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance May 04, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old April 24, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call April 20, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences February 27, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results February 16, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old February 13, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire 3 No-Brainer Stocks to Buy Right Now for Less Than $25 February 04, 2023 All three healthcare stocks are showing solid long-term potential. Via The Motley Fool Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call February 02, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Why Ironwood Pharmaceuticals Shares Are Falling During Monday's Session January 09, 2023 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares are trading lower by 10.00% to $11.30 Monday afternoon after the company cut its FY22 sales guidance below analyst estimates and issued FY23 sales... Via Benzinga Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance January 09, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference January 04, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference November 22, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals: Q3 Earnings Insights November 03, 2022 Ironwood Pharmaceuticals (NASDAQ:IRWD) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Via Benzinga Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance November 03, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call October 20, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Shares Positive Top-line Data From Late-Stage Functional Constipation Candidate Study In Patients Aged 6-17 Years September 06, 2022 Ironwood Pharmaceuticals (NASDAQ: IRWD) announced positive top-line data from its Phase 3 clinical trial evaluating LINZESS (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional... Via Benzinga Ironwood's Constipation Drug Shows Efficacy In Pediatric Patients September 06, 2022 Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) announced topline data from a Phase 3 trial evaluating Linzess (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation. Via Benzinga Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation September 06, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference September 01, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Wells Fargo Maintains Equal-Weight Rating for Ironwood Pharmaceuticals: Here's What You Need To Know August 16, 2022 Wells Fargo has decided to maintain its Equal-Weight rating of Ironwood Pharmaceuticals (NASDAQ:IRWD) and raise its price target from $12.00 to $13.00. Shares of Ironwood Pharmaceuticals are trading... Via Benzinga Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand August 04, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.